Prenatal Programming of Metabolic Syndrome in the Common Marmoset Is Associated With Increased Expression of 11β-Hydroxysteroid Dehydrogenase Type 1

被引:50
|
作者
Nyirenda, Moffat J. [1 ]
Carter, Roderick [1 ]
Tang, Justin I. [1 ]
de Vries, Annick [1 ]
Schlumbohm, Christina [2 ]
Hillier, Stephen G. [3 ]
Streit, Frank [4 ]
Oellerich, Michael [4 ]
Armstrong, Victor W. [4 ]
Fuchs, Eberhard [2 ]
Seckl, Jonathan R. [1 ]
机构
[1] Univ Edinburgh, Endocrinol Unit, Queens Med Res Inst, Edinburgh EH8 9YL, Midlothian, Scotland
[2] Leibniz Inst Primate Res, Clin Neurobiol Lab, German Primate Ctr, Gottingen, Germany
[3] Univ Edinburgh, MRC, Reprod Sci Unit, Queens Med Res Inst, Edinburgh EH8 9YL, Midlothian, Scotland
[4] Univ Gottingen, Dept Clin Chem, Gottingen, Germany
关键词
TISSUE-SPECIFIC DYSREGULATION; GLUCOCORTICOID METABOLISM; INSULIN-RESISTANCE; GLUCOSE-METABOLISM; ADIPOSE-TISSUE; OBESITY; CORTISOL; RATS; DISEASE; MICE;
D O I
10.2337/db09-0873
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE-Recent studies in humans and animal models of obesity have shown increased adipose tissue activity of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1), which amplifies local I issue glucocorticoid concentrations. The reasons for this 11 beta-HSD1 dystegulation are unknown. Here, we tested whether 11 beta-HSD1 expression, like the metabolic syndrome, is "programmed" by prenatal environmental events in a nonhuman primate model, the common marmoset monkey. RESEARCH DESIGN AND METHODS-We used a "fetal programming" paradigm where brief antenatal exposure to glucocorticoids leads to the metabolic syndrome in the offspring. Pregnant marmosets were given the synthetic glucocorticoid dexamethasone orally for 1 week in either early or late gestation, or they were given vehicle. Tissue 11 beta-HSD1 and glucocorticoid receptor mRNA expression were examined in the offspring at 4 and 24 months of age. RESULTS-Prenatal dexamethasone administration, selectively during late gestation, resulted in early and persistent elevations in 11 beta-HSD1 mRNA expression and activity in the liver, pancreas, and subcutaneous-but not visceral-fat. The increase in 11 beta-HSD1 occurred before animals developed obesity or overt features of the metabolic syndrome. In contrast to rodents, in utero dexamethasone exposure did not alter glucocorticoid receptor expression in metabolic tissues in marmosets. CONCLUSIONS-These data suggest that long-term upregulation of 11 beta-HSD1 in metabolically active tissues may follow prenatal "stress" hormone exposure and indicates a novel mechanism for fetal origins of adult obesity and the metabolic syndrome. Diabetes 58:2873-2879, 2009
引用
收藏
页码:2873 / 2879
页数:7
相关论文
共 50 条
  • [31] 11β-Hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes
    Morgan, Stuart A.
    Tomlinson, Jeremy W.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (09) : 1067 - 1076
  • [32] Evolution of 11β-hydroxysteroid dehydrogenase-type 1 and 11β-hydroxysteroid dehydrogenase-type 3
    Baker, Michael E.
    FEBS LETTERS, 2010, 584 (11) : 2279 - 2284
  • [33] Tissue-specific Cushing's syndrome uncovers a new target in treating the metabolic syndrome -: 11β-hydroxysteroid dehydrogenase type 1
    Stewart, PM
    CLINICAL MEDICINE, 2005, 5 (02) : 142 - 146
  • [34] 11β-Hydroxysteroid dehydrogenase type 1 inhibitors with oleanan and ursan scaffolds
    Blum, Andreas
    Favia, Angelo D.
    Maser, Edmund
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2009, 301 (1-2) : 132 - 136
  • [35] Tissue production of cortisol by 11β-hydroxysteroid dehydrogenase type 1 and metabolic disease
    Walker, Brian R.
    Andrew, Ruth
    STRESS, OBESITY, AND METABOLIC SYNDROME, 2006, 1083 : 165 - 184
  • [36] 11β-Hydroxysteroid Dehydrogenase Type 1 in Obese Subjects With Type 2 Diabetes Mellitus
    Li, Xia
    Wang, Jingli
    Yang, Qin
    Shao, Shiying
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2017, 354 (04) : 408 - 414
  • [37] Inhibition of 11β-hydroxysteroid dehydrogenase type 1 ameliorates obesity-related insulin resistance
    Shao, Shiying
    Zhang, Xiaojie
    Zhang, Muxun
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 478 (01) : 474 - 480
  • [38] 11β-hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes
    Stulnig, TM
    Waldhäusl, W
    DIABETOLOGIA, 2004, 47 (01) : 1 - 11
  • [39] 11β-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes
    T. M. Stulnig
    W. Waldhäusl
    Diabetologia, 2004, 47 : 1 - 11
  • [40] Selective Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 for Patients With Metabolic Syndrome Is the Target Liver, Fat, or Both?
    Stewart, Paul M.
    Tomlinson, Jeremy W.
    DIABETES, 2009, 58 (01) : 14 - 15